Skip Navigation


Rheumatology Advance Access originally published online on June 30, 2009
Rheumatology 2009 48(9):1177-1178; doi:10.1093/rheumatology/kep163
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
48/9/1177    most recent
kep163v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mangat, P.
Right arrow Articles by Abraham, S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mangat, P.
Right arrow Articles by Abraham, S.
Related Collections
Right arrow Spondylarthropathies
Right arrow Pharmacology
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Comment on: Possible miliary tuberculosis during adalimumab therapy with negative {gamma}-IFN release assays

Pamela Mangat1,2, Peter Taylor1,2 and Sonya Abraham1,2

1Kennedy Institute of Rheumatology Division, Imperial College London and 2Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK

Correspondence to: Pamela Mangat, Kennedy Institute of Rheumatology Division, Imperial College London, 65 Aspenlea Road, Hammersmith, Greater London W6 8LH, UK. E-mail: Pamela.mangat@imperial.ac.uk

The first 10% of the full text of this article appears below.

SIR, We read with interest the case of ‘Possible miliary tuberculosis during adalimumab therapy with negative {gamma}-IFN release assays’ published by Endean et al. [1]. We suggest that the negative QuantiFERON-TB . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
A. L. Endean, S. M. Barry, and S. A. Young-Min
Comment on: Possible miliary tuberculosis during adalimumab therapy with negative {gamma}-IFN release assays: reply
Rheumatology, September 1, 2009; 48(9): 1178 - 1178.
[Full Text] [PDF]